Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Marked Increase of CYP24A1 mRNA Level in Hepatocellular Carcinoma Cell Lines Following Vitamin D Administration

EVELIN HORVATH, PÉTER LAKATOS, BERNADETT BALLA, JÁNOS PÁL KÓSA, BÁLINT TÓBIÁS, HASAN JOZILAN, KATALIN BORKA, HENRIK CSABA HORVÁTH, ILONA KOVALSZKY and FERENC SZALAY
Anticancer Research November 2012, 32 (11) 4791-4796;
EVELIN HORVATH
1First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: horvath.evelyn@gmail.com
PÉTER LAKATOS
1First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BERNADETT BALLA
1First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JÁNOS PÁL KÓSA
1First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BÁLINT TÓBIÁS
1First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HASAN JOZILAN
1First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATALIN BORKA
2Second Department of Pathology, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HENRIK CSABA HORVÁTH
1First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ILONA KOVALSZKY
3First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FERENC SZALAY
1First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) inhibits cell growth and induces apoptosis in numerous types of tumors. We aimed to examine the mRNA and protein expression of 1,25(OH)2D3-inactivating CYP24A1 and mRNA expression of the activating CYP27B1 enzymes, as well as that of vitamin D receptor (VDR), in hepatocellular carcinoma (HCC) cell cultures in response to 1,25(OH)2D3 administration. Materials and Methods: Increasing amounts of 1,25(OH)2D3 (0.256-10 nM) were added to cultures of HepG2, Huh-Neo, Hep3B, Huh5-15 human HCC cell lines and cells then incubated for various time periods (30 min–28 h). The mRNA expression was analyzed by real time reverse transcription-polymerase chain reaction (RT-PCR). CYP24A1 protein in HepG2 cells was detected by immuncytochemistry. Results: CYP24A1 mRNA expression significantly (p<0.0001) increased in response to 1,25(OH)2D3 administration in two cell lines: in HepG2 cells, the CYP24A1 mRNA level exhibited 5,300-fold elevation, reaching a maximum value at 8 h; in Huh-Neo cells, the increase was 152-fold that of the baseline value, with the maximum being reached at 14 h. There was no significant change in Hep3B and Huh5-15 cell lines, nor was there any change in CYP27B1 and VDR gene expression in any cell cultures. Immuncytochemistry in HepG2 cells proved that gene activation was followed by CYP24A1 protein synthesis. Conclusion: Our novel data indicate that administration of 1,25(OH)2D3 results in a marked increase of CYP24A1 mRNA expression in some, but not all, human HCC lines in vitro. These differences could be dependent upon the origin of the tumor cells.

  • Hepatocellular carcinoma
  • 1,25-dihydroxyvitamin D3
  • CYP24A1
  • mRNA expression
  • HepG2

Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumors worldwide. Despite great progress in our understanding over the molecular mechanisms of hepatocarcinogenesis, many regulatory processes are still unknown. 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the active form of vitamin D, inhibits cell growth and induces apoptosis in numerous tumor types such as colon, breast and prostate cancer. An antitumor effect of 1,25(OH)2D3 on liver cancer cells has been detected in vitro. The clinical use of 1,25(OH)2D3 for HCC is limited since the dose of vitamin D exerting antitumor effects induces hypercalcemia in vivo (1). Several 1,25(OH)2D3 analogs without hypercalcemic effect were tested for the treatment of HCC in pre-clinical studies (2-4). The antitumor effect of vitamin D analogs was variable in patients with HCC but the cause of such individual differences in response remains unknown (5). The actual concentration of vitamin D available in tissues depends on the balance between activating and inactivating enzymes.

In order to study vitamin D metabolism in HCC, we examined the mRNA and protein expression of 1,25(OH)2D3-inactivating 24-hydroxylase (CYP24A1) and the mRNA expression of the activating 25-hydroxyvitamin D-1-alpha-hydroxylase (CYP27B1) enzymes, as well as that of vitamin D receptor (VDR) in four HCC cell lines in response to 1,25(OH)2D3 administration.

Materials and Methods

Ethics. This work has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. This study was approved ethically by the Regional Committee of Science and Research Ethics, Semmelweis University (ETT TUKEB 5637-0/2010-1018EKU – 402/PI/010).

Cell lines and culture conditions. Experiments were performed on four human hepatocellular carcinoma cell lines: HepG2, Huh-Neo, Huh5-15 and Hep3B. The Huh-Neo and Huh5-15 cell lines were received as gift from the Department of Molecular Virology, University of Heidelberg, Germany. The Huh-Neo cell line contains the gene for neomycin phosphotransferase (NPT) and is resistant to neomycin (6). Huh5-15 cells, containing the subgenomic hepatitis C virus (HCV) replicon I389hyg-ubi/NS3-3’ were provided by R. Bartenschlager at the University of Heidelberg (7, 8). HepG2 (ATCC® no. HB-8065 HepG2) was originally derived from the liver tissue of a 15-year-old Caucasian American male with a well-differentiated hepatocellular carcinoma (Sigma-Aldrich, St. Louis, MO, USA). Hep3B is a well-differentiated human hepatoma cell line from an 8-year-old black male, and contains an integrated HBV genome (Sigma-Aldrich) (9, 10).

Cells were cultured in Dulbecco's Modified Eagle's Medium (Life Technologies – Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum (Life Technologies – Invitrogen), 1 mM sodium pyruvate (Sigma-Aldrich), 100 IU penicillin, 100 g/ml streptomycin and 4 mM glutamine (all from Life Technologies – Invitrogen) at 37°C, in a humidified atmosphere of 95% air and 5% CO2. Media were changed every second day.

Subcultures were carried out as follows: After removal of medium, cells were rinsed with 2 ml of trypsin-EDTA solution, with sitting the flask at room temperature until the cells detached, followed by the addition of fresh culture medium, aspirating and dispensing cells into new culture flasks.

Incubation with 1,25(OH)2D3. 1,25-(OH)2D3 (Sigma-Aldrich) was dissolved in ethanol at 100 M and diluted in Opti-MEM (Life Technologies – Invitrogen) to give a final ethanol concentration of 0.1%. Control cultures were treated with Opti-MEM containing ethanol (0.1%) vehicle-only. Each HCC cell line was incubated with 1 nM and 10 nM vitamin D for 5 h in Opti-MEM at 37°C in a humidified atmosphere of 95% air and 5% CO2. Cells were harvested and CYP24A1, CYP27B1 and VDR mRNA expressions were measured. In dose-response experiments, cells were incubated with different doses of 1,25-(OH)2D3 (0.256, 0.64, 1.6, 4.0, 10.0 nM) for 5 h in two parallel series. To measure the time course of mRNA responses, cells were incubated with 4 nmol of 1,25-(OH)2D3 for 30 min, and 1, 2, 5, 8, 10, 12, 14, 24, 26 and 28 h in two parallel series under normal growth conditions. Treatment solutions containing 1,25(OH)2D3 were prepared in serum-free Opti-MEM for all experiments. All experiments were repeated at least three times.

RNA isolation, cDNA synthesis and quantitative reverse transcription-PCR (qRT-PCR). Total RNA was isolated from the cell cultures with Roche High Pure Total RNA Isolation Kit (Roche, Indianapolis, IN, USA). The procedure was performed following the manufacturer's instructions. Five-hundred nanograms of total RNA were reverse-transcribed to cDNA (Promega, Madison, WI, USA). Pre-designed and validated gene-specific TaqMan Gene Expression Assays from Applied Biosystems (Life Technologies – Invitrogen) were used in triplicate for quantitative real-time PCR according to the manufacturer's protocol. Every set contained gene-specific forward and reverse primers and fluorescence labeled probes. Probes span an exon junction and do not detect genomic DNA (Applied Biosystems TaqMan® Assays numbers were Hs00167999_m1 for CYP24A1, Hs99999905_m1 for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Hs00168017_m1 for CYP27B1 and Hs00172113_m1 for VDR, respectively). PCR assays were used with the following protocol: 10 min denaturation at 95°C, and 45 cycles of 15 s denaturation at 95°C, followed by 1 min annealing and extension at 60°C. The PCR reaction volume was 20 μl containing 2 μl cDNA, 10 μl TaqMan ×2 Universal PCR Master Mix NoAmpErase UNG (Applied Biosystems), 1 μl gene-specific TaqMan Gene Expression Assay Mix and 7 μl water. GAPDH was used as a housekeeping gene to normalize for RNA loading. Samples were analyzed using ABI Prism 7500 real-time PCR system (Applied Biosystems). Relative quantification (RQ) studies were carried out from collected data (threshold cycle numbers, referred to as Ct) with 7500 System SDS software 1.3 (Applied Biosystems).

Immunocytochemistry. Cells were cultured on special slides in the same way as described above (Cell lines and culture conditions). Lab-Tek® Chamber Slide™and Lab-Tek® Chambered Coverglass (Thermo Fisher Scientific GmbH, Bremen, Germany) were used for these experiments.

Immunocytochemistry for CYP24A1 was performed using the two-step indirect immunoperoxidase technique. WH0001591M7 (monoclonal anti-CYP24A1, clone 1F8 antibody produced in mouse; Sigma-Aldrich) antibody was used. Normal kidney sections were used as a positive control. Staining was carried out following the manufacturer's instructions. Expression of CYP24A1 was evaluated semi-quantitatively. Ten randomly selected areas of each slide were manually analyzed using the high-power field objective (×40), with 500 cells counted per field. Immunoreactions were scored as positive where nuclear staining was seen.

Statistical analysis. Data were analyzed using the SPSS for Windows, release 18 (IBM, Armonk, NY, USA). Final data are presented as the means of two independent measurements. Results are expressed as mean±standard error of the mean (S.E.M.). Statistical analysis was performed using the unpaired Student's t-test; results with a p-value of 0.05 or less were considered statistically significant.

Results

CYP24A1, CYP27B1 and VDR mRNA changes following 1,25(OH)2D3 administration. Basal CYP24A1 mRNA expression was very low in all of cell lines. Exposure to 1,25-(OH)2D3 both at doses of 1 nM and 10 nM for 5 h, resulted in a strongly significant (p<0.0001) expression of CYP24A1 mRNA in HepG2 and Huh-Neo cell lines, but had no effect on Huh5-15 and Hep3B cells at the investigated time point (5 h). In HepG2 cells, the increase of CYP24A1 mRNA expression was more pronounced, close to 1,000-fold (Figure 1A) compared to Huh-Neo cells, which exhibited a 100-fold increase after 5 h of incubation (Figure 1B). In HepG2 cells, the larger dose of vitamin D did not result in a further increase of mRNA expression compared to the effect of 1 nM. In Huh-Neo cells, the magnitude of the mRNA elevation was smaller (p<0.001), and in this set, 10 nM of vitamin D neither resulted in a further significant increase of mRNA expression.

There was no change in CYP27B1 or VDR mRNA expressions in any of the examined cell lines after 5 h of 1,25-(OH)2D3 incubation neither at 1 nM nor at 10 nM.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

24-hydroxylase (CYP24A1) mRNA expression changes in response to 1,25-dihydroxyvitamin [1,25(OH)2D3)]. HepG2 (A) and Huh-Neo (B) cell lines were incubated with 1 nmol/l and 10 nmol/l active vitamin D for a duration of 5 h. Cells without 1,25(OH)2D3 incubation were used as controls. ***p<0.0001. AU: Arbitrary units.

Dose-dependent increase of CYP24A1 expression in HepG2 and Huh-Neo cells. We found a dose-dependent increase in CYP24A1 expression in HepG2 and Huh-Neo cell lines in response to 1,25(OH)2D3 administration for 4 h. In concordance with the first set of experiments, the response of HepG2 cells was larger than that of Huh-Neo cells at each dose (Figure 2). In Hep G2 cells, 1.6 nM 1,25(OH)2D3 resulted in significant elevation of mRNA (p<0.001), while in Huh-Neo cells, the elevation reached significance only at a dose of 4.0 nM. The difference between the two cell types in CYP24A1 mRNA expression was one order of magnitude using 1.6, 4.0 and 10.0 nM 1,25(OH)2D3. In HepG2 cells, 180-, 820-, and 1,010-fold elevations were detected versus 2.0-, 38-, and 140-fold increases in Huh-Neo cells at 1.6, 4.0, and 10 nM, respectively.

Different time curves of CYP24A1 mRNA expression in HepG2 and Huh-Neo cells. Not only was the magnitude of CYP24A1 mRNA expression found to be different in HepG2 and Huh-Neo cells but so was the kinetics of expression. In HepG2 cells, the CYP24A1 mRNA expression exhibited a 5,300-fold elevation, reaching its maximum value at 8 h. In Huh-Neo cells, the increase was 152-fold that of the baseline and the maximum was reached at 14 h (Figure 3).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

24-hydroxylase (CYP24A1) mRNA dose-response curves of HepG2 (A) and Huh-Neo (B) cell lines in response to 1,25-dihydroxyvitamin [1,25(OH)2D3]. The cells were treated with increasing concentrations of 1,25(OH)2D3 from 0.256 nmol/l up to 10 nmol/l for 4 h. Cells without 1,25(OH)2D3 incubation were used as controls. ***p<0.0001. AU: Arbitrary units.

CYP24A1 protein expression by immunocytochemistry. Immunocytochemistry showed that gene activation with 1,25(OH)2D3 was followed by CYP24A1 protein synthesis, indicating effective translation. Strong CYP24A1 enzyme staining was shown in HepG2 cells after 32 h of incubation with 4 nM 1,25(OH)2D3, whereas no staining was observed in the untreated control cells (Figure 4). Expression of CYP24A1 was confined to the cytoplasm; the punctuated pattern of the staining is consistent with mitochondrial localization of the enzyme.

Discussion

HCC is the fifth most common type of cancer in men and the seventh in women (11). Despite preventative and therapeutic efforts, the annual death rate is over seven million worldwide (12). The discovery of the antitumor effect of 1,25(OH)2D3 on various malignancies, such as breast and colon carcinoma, melanoma and also HCC opened up an opportunity for treatment (13-16). However, the clinical use of 1,25(OH)2D3 in HCC is limited by its hypercalcemic effect due to the relatively large doses required in order for it to exert its antitumor effect (1). The use of vitamin D analogs without hypercalcemic effect is the object of pre-clinical and clinical studies (17, 18).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

24-hydroxylase (CYP24A1) mRNA time course curves of HepG2 (A) and Huh-Neo (B) cell lines in response to 1,25-dihydroxyvitamin [1,25(OH)2D3]. *p<0.0001. AU: Arbitrary units.

Increased activity of CYP24A1, the key neutralizing enzyme of 1,25(OH)2D3 was found in colon, lung, prostate, thyroid, breast and ovarian cancer cells (19-22). To our knowledge, this is the first study on CYP24A1 mRNA expression in HCC lines in vitro. Our novel data on the marked increase of CYP24A1 mRNA and protein expression in HepG2 and Huh-Neo cell lines in response to 1,25(OH)2D3 indicate that these HCC cells are capable of metabolizing 1,25(OH)2D3 autonomously. The differences in CYP24A1 mRNA response to 1,25(OH)2D3 among HCC cell lines of different origin might explain individual differences in responses of patients to vitamin D treatment.

Similarly, differences were reported among cervical and ovarian cancer cells (23). In our study, only two out of four HCC cell lines exhibited an increase in CYP24A mRNA following incubation with 1,25(OH)2D3. We found a one-magnitude higher increase of CYP24A mRNA in HepG2 cells than that which others observed in ovarian cancer cells (OVCAR-3), despite the fact that a much higher concentration of 1,25(OH)2D3 was used in those experiments (100 nM as compared to 4 nM in our study). These data suggest that these HCC cell lines are much more sensitive to 1,25(OH)2D3 in responding with CYP24A1 expression. The cause of differences in magnitude and kinetics of CYP24A1 mRNA expression between HepG2 and Huh-Neo cells needs further study.

The magnitude of the increase of CYP24A1 mRNA expression in HepG2 cells (5,300-fold) following 1,25(OH)2D3 administration is in concordance with the expert of response of DU-145 prostate cancer cells and some colon cancer cell lines (Caco-2 and COGA-1) which also exhibit high expression of this metabolizing enzyme (19, 24).

The antiproliferative effect of 1,25(OH)2D3 on HepG2 cells has been published and 100 μM was found to be the lowest effective inhibiting dose (3). We have shown here, that a significantly smaller dose of 1,25(OH)2D3 induces activation of CYP24A mRNA, which could lead to an accelerated metabolism and a reduced antitumor effect of 1,25(OH)2D3.

Based on our results, the antitumor effect of 1,25(OH)2D3 or vitamin D analogs could be increased in HCC by combination with CYP24A1 enzyme inhibitors. This has been reported in human prostate cancer cells in vitro and in an animal experiment (24). As CYP24A1 was suggested as a candidate oncogene in colon and breast cancer, the same possibility could arise in some HCC cell lines (25, 26).

Major risk factors for hepatocellular carcinoma include infection with HBV or HCV. Recent evidence shows that the serum vitamin D level could have a possible role in predicting the outcome of antiviral therapy in patients with chronic HCV infection (27). Thus, the higher risk for HCC in antiviral treatment-resistant patients might also be related to the low vitamin D levels. However, we did not detect CYP24A1 mRNA response to 1,25(OH)2D3 in Huh5-15 HCC cells, which contain integrated HCV genome.

Despite the increase in CYP24A1 mRNA expression, we did not detect significant changes in VDR mRNA expression in our experimental design. This is consistent with a previous report that in human breast and colon cancer cells, 1,25(OH)2D3 profoundly stimulated CYP24A1 mRNA but did not affect VDR mRNA expression (28). However, based on observations on melanoma and breast cancer cell lines, the regulation of expression of 1,25(OH)2D3 target genes is very complex and not only depends on the type of vitamin D response element but also on a multitude of co-activators and co-repressors, and on other unknown mechanisms (29, 30).

In concordance with findings on other carcinoma cell lines, we also did not find changes in CYP27B1 mRNA expression after 1,25(OH)2D3 administration (19).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Immunochemical detection of 24-hydroxylase (CYP24A1) enzyme expression. A: Normal kidney sections served as positive controls. A brown color indicates a positive reaction. Nuclei are counterstained with hematoxylin (blue) (×200 magnification). B: Negative control: HepG2 cells without 1,25-dihydroxyvitamin [1,25(OH)2D3] administration (×20 magnification). C: Detection of CYP24A1 enzyme protein in HepG2 cell cultures by immunochemical staining at 32 hours after administration of 4 nM 1,25(OH)2D3 (×20 magnification).

In conclusion, our novel data indicate that administration of 1,25(OH)2D3 results in a marked increase of CYP24A1 mRNA expression in some, but not all HCC cell lines in vitro. The differences in response to 1,25(OH)2D3 might be dependent upon of the origin of the tumor cells. It can be speculated that increased expression of CYP24A1 protects cancer cells from the anticancer effects of 1,25(OH)2D3. Combining 1,25(OH)2D3 with CYP24A1 enzyme inhibitors could be an approach to new antitumor drug development.

Acknowledgements

The study was approved by the Regional Committee of Science and Research Ethics, Semmelweis University (ETT TUKEB 5637-0/2010-1018EKU – 402/PI/010.) and supported by a Scientific Project Grant, Semmelweis University.

Footnotes

  • Conflicts of Interest

    The Authors declare no financial or commercial conflict of interest.

  • Received July 13, 2012.
  • Revision received September 16, 2012.
  • Accepted September 18, 2012.
  • Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Spina CS,
    2. Tangpricha V,
    3. Uskokovic M,
    4. Adorinic L,
    5. Maehr H,
    6. Holick MF
    : Vitamin D and cancer. Anticancer Res 26: 2515-2524, 2006.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Luo W,
    2. Chen J,
    3. Zhang X,
    4. Wang W
    : Regulatory mechanism of EB1089 for hepatocarcinoma cell proliferation. Wei Sheng Yen Chiu 33: 140-143, 2004.
    OpenUrlPubMed
  3. ↵
    1. Akhter J,
    2. Lu Y,
    3. Finlay I,
    4. Pourgholami MH,
    5. Morris DL
    : 1α,25-Dihydroxyvitamin D3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2. ANZ J Surg 71: 414-417, 2001.
    OpenUrlPubMed
  4. ↵
    1. Dalhoff K,
    2. Dancey J,
    3. Astrup L,
    4. Skovsgaard T,
    5. Hamberg KJ,
    6. Lofts FJ,
    7. Rosmorduc O,
    8. Erlinger S,
    9. Bach Hansen J,
    10. Steward WP,
    11. Skov T,
    12. Burcharth F,
    13. Evans TR
    : A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 89: 252-257, 2003.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ghous Z,
    2. Akhter J,
    3. Pourgholami MH,
    4. Morris DL
    : Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. Anticancer Res 28(6A): 3757-3761, 2008.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Cagnon L,
    2. Wagaman P,
    3. Bartenschlager R,
    4. Pietschmann T,
    5. Gao T,
    6. Kneteman NM,
    7. Tyrrell DL,
    8. Bahl C,
    9. Niven P,
    10. Lee S,
    11. Simmen KA
    : Application of the trak-C HCV core assay for monitoring antiviral activity in HCV replication systems. J Virol Methods 118(1): 23-31, 2004.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Frese M,
    2. Barth K,
    3. Kaul A,
    4. Lohmann V,
    5. Schwärzle V,
    6. Bartenschlager R
    : Hepatitis C virus RNA replication is resistant to tumour necrosis factor-α. J Gen Virol 84: 1253-1259, 2003.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Lohmann V,
    2. Körner F,
    3. Koch J,
    4. Herian U,
    5. Theilmann L,
    6. Bartenschlager R
    : Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113, 1999.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Knowles BB,
    2. Howe CC,
    3. Aden DP
    : Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499, 1980.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Hsu SL,
    2. Lin YF,
    3. Chou CK
    : Retinoic acid biphasically regulates the gene expression of hepatitis B virus surface antigen in human hepatoma Hep3B cells. J Biol Chem 268: 23093-23097, 1993.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. El-Serag HB
    : Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
    OpenUrlCrossRefPubMed
  12. ↵
    1. WHO
    , Cancer Fact Sheet No. 296, World Health Organization, www.who.int/mediacentre/factsheets, 2006.
  13. ↵
    1. Colston KW,
    2. Berger U,
    3. Coombes RC
    : Possible role for vitamin D in controlling breast cancer proliferation. Lancet 1: 188-189, 1989.
    OpenUrlPubMed
    1. Akhter J,
    2. Goerdel M,
    3. Morris DL
    : A vitamin D3 analogue (EB1089) inhibits in vitro cellular proliferation of human colon cancer cells. Br J Surg 83: 229-230, 1996.
    OpenUrlCrossRefPubMed
    1. Colston K,
    2. Colston MJ,
    3. Feldman D
    : 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108(3): 1083-1086, 1981.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Pourgholami MH,
    2. Akhter J,
    3. Lu Y,
    4. Morris DL
    : In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett 151(1): 97-102, 2000.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Pourgholami MH,
    2. Morris DL
    : 1,25-Dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. J Steroid Biochem Mol Biol 89-90(1-5): 513-518, 2004.
    OpenUrlPubMed
  16. ↵
    1. Morris DL,
    2. Jourdan JL,
    3. Finlay I,
    4. Gruenberger T,
    5. The MP,
    6. Pourgholami MH
    : Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma. Int J Oncol 21(4): 901-906, 2002.
    OpenUrlPubMed
  17. ↵
    1. Lechner D,
    2. Kállay E,
    3. Cross HS
    : 1Alpha,25-dihydroxyvitamin D3 down-regulates CYP27B1 and induces CYP24A1 in colon cells. Mol Cell Endocrinol 263(1-2): 55-64, 2007.
    OpenUrlCrossRefPubMed
    1. Parise RA,
    2. Egorin MJ,
    3. Kanterewicz B,
    4. Taimi M,
    5. Petkovich M,
    6. Lew AM,
    7. Chuang SS,
    8. Nichols M,
    9. El-Hefnawy T,
    10. Hershberger PA
    : CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 119(8): 1819-1828, 2006.
    OpenUrlCrossRefPubMed
    1. Balla B,
    2. Kósa JP,
    3. Tobiás B,
    4. Halászlaki C,
    5. Takács I,
    6. Horváth H,
    7. Speer G,
    8. Nagy Z,
    9. Horányi J,
    10. Járay B,
    11. Székely E,
    12. Lakatos P
    : Marked increase in CYP24A1 gene expression in human papillary thyroid cancer. Thyroid 21(4): 459-60, 2011.
    OpenUrlPubMed
  18. ↵
    1. Lopes N,
    2. Sousa B,
    3. Martins D,
    4. Gomes M,
    5. Vieira D,
    6. Veronese LA,
    7. Milanezi F,
    8. Paredes J,
    9. Costa JL,
    10. Schmitt F
    : Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10: 483, 2010.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Kloss M,
    2. Fischer D,
    3. Thill M,
    4. Friedrich M,
    5. Cordes T,
    6. Salehin D,
    7. Diedrich K,
    8. Köster F
    : Vitamin D, calcidiol and calcitriol regulate vitamin D metabolizing enzymes in cervical and ovarian cancer cells. Anticancer Res 30(11): 4429-4434, 2010.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Muindi JR,
    2. Yu WD,
    3. Ma Y,
    4. Engler KL,
    5. Kong RX,
    6. Trump DL,
    7. Johnson CS
    : CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 151(9): 4301-4312, 2010.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Albertson DG,
    2. Ylstra B,
    3. Segraves R,
    4. Collins C,
    5. Dairkee SH,
    6. Kowbel D,
    7. Kuo WL,
    8. Gray JW,
    9. Pinkel D
    : Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25(2): 144-146, 2000.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Horváth HC,
    2. Lakatos P,
    3. Kósa JP,
    4. Bácsi K,
    5. Borka K,
    6. Bises G,
    7. Nittke T,
    8. Hershberger PA,
    9. Speer G,
    10. Kállay E
    : The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 58(3): 277-285, 2010.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Bitetto D,
    2. Fattovich G,
    3. Fabris C,
    4. Ceriani E,
    5. Falleti E,
    6. Fornasiere E,
    7. Pasino M,
    8. Ieluzzi D,
    9. Cussigh A,
    10. Cmet S,
    11. Pirisi M,
    12. Toniutto P
    : Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 53(4): 1118-1126, 2011.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Anderson MG,
    2. Nakane M,
    3. Ruan X,
    4. Kroeger PE,
    5. Wu-Wong JR
    : Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57(2): 234-240, 2006.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Zella LA,
    2. Kim S,
    3. Shevde NK,
    4. Pike JW
    : Enhancers located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. Mol Endocrinol 20: 1231-1247, 2006.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Cordes T,
    2. Diesing D,
    3. Becker S,
    4. Diedrich K,
    5. Reichrath J,
    6. Friedrich M
    : Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative breast cancer cell lines. Anticancer Res 26(4A): 2749-2753, 2006.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 32 (11)
Anticancer Research
Vol. 32, Issue 11
November 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Marked Increase of CYP24A1 mRNA Level in Hepatocellular Carcinoma Cell Lines Following Vitamin D Administration
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Marked Increase of CYP24A1 mRNA Level in Hepatocellular Carcinoma Cell Lines Following Vitamin D Administration
EVELIN HORVATH, PÉTER LAKATOS, BERNADETT BALLA, JÁNOS PÁL KÓSA, BÁLINT TÓBIÁS, HASAN JOZILAN, KATALIN BORKA, HENRIK CSABA HORVÁTH, ILONA KOVALSZKY, FERENC SZALAY
Anticancer Research Nov 2012, 32 (11) 4791-4796;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Marked Increase of CYP24A1 mRNA Level in Hepatocellular Carcinoma Cell Lines Following Vitamin D Administration
EVELIN HORVATH, PÉTER LAKATOS, BERNADETT BALLA, JÁNOS PÁL KÓSA, BÁLINT TÓBIÁS, HASAN JOZILAN, KATALIN BORKA, HENRIK CSABA HORVÁTH, ILONA KOVALSZKY, FERENC SZALAY
Anticancer Research Nov 2012, 32 (11) 4791-4796;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Vitamin D Effect on Growth and Vitamin D Metabolizing Enzymes in Triple-negative Breast Cancer
  • Google Scholar

More in this TOC Section

  • The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases
  • Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer
  • Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer
Show more Experimental Studies

Similar Articles

Keywords

  • hepatocellular carcinoma
  • 1,25-dihydroxyvitamin D3
  • CYP24A1
  • mRNA expression
  • HepG2
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire